血清高敏感C反應蛋白與十年冠心病危險指數的相關性

The Relationship between Serum C-Reactive Protein and the Framingham Coronary Heart Disease Risk Score in Overweight Middle-aged Hospital Employees

10.7023/TJFM.200603.0041

黃麗卿(Lee-Ching Hwang)；詹欣隆(Hsin-Lung Chan)；黃俊雄(Chun-Hsiung Huang)

C-reactive protein ； prevention ； coronary heart disease ； risk score

台灣家庭醫學雜誌

16卷1期（2006 / 03 / 01）

41 - 50

繁體中文

預測心臟血管疾病的危險性是預防醫學中重要的常規工作，使用工具以the Framingham Coronary Heart Disease Risk Score (FCRS)為主，而近年來研究文獻發現血清高敏感C反應蛋白(hs-CRP)可以預測心臟血管疾病的危險性，本研究的目的在探討hs-CRP與冠狀動脈心臟病十年預測值的相關。 本研究收集某醫院員工體檢體重過重，身體質量指數(BMI)大於24kg/m^2者331人參與本研究進入健康促進計劃，以問卷填寫方式，登錄個案基本資料和抽菸飲酒習慣，運動習慣狀況評估，並測量身高、體重、腰臀圍與血壓，血液檢查包含空腹血糖值、hs-CRP、總膽固醇、低密度脂蛋白膽固醇、高密度脂蛋白膽固醇、三酸甘油酯等；計算FCRS，估計十年冠狀動脈心臟病發生率預測值。 結果發現無論性別，hs-CRP分成四百分位後，隨著百分位升高，十年冠狀動脈心臟病發生率預測值升高，且與BMI、腰圍及空腹血糖值也有統計上顯著的正相關，而在男性，hs-CRP與血壓值呈正相關，而與高密度脂蛋白膽固醇呈負相關。在邏輯回歸分析時，十年冠狀動脈心臟病發生率預測值高於同年齡性別預測值的狀況，hs-CRP第四百分位組相較於第一百分位組的危險對比值男性為3.6、女性為4.2，經調整腹部肥胖與否後，仍具統計相關。 在體重過重之中年人，血清hs-CRP升高會增加十年冠狀動脈心臟病發生率預測值。

The Framingham Coronary Heart Disease Risk Score (FCRS) is recommended for global risk assessment in subjects prone to coronary heart disease (CHD). Recently, high sensitivity C-reactive protein (hs-CRP) has emerged as an independent predictor of CHD, but few data are available evaluating the relationship between hs-CRP and FCRS. We sought to assess the association of hs-CRP levels with FCRS in a cross-sectional study of middle-aged hospital employees. The participants were recruited from the Strong Heart Program of Mackay Memorial Hospital in Taipei from Jul 2004 to Feb 2005 for health promotion activities. This study comprised 331 participants who were overweight with BMI≧24 kg/m^2. Medical history, life style, physical examination, body weight and height, waist and hip circumference, blood pressure and laboratory tests including hs-CRP were assessed. We calculated the predicted 10 years CHD incidence by the FCRS. According to the quartiles of hs-CRP, subjects were classified into four groups. Among women and men, calculated 10 years CHD incidence increased from bottom to top groups of hs-CRP. Body mass index, waist circumference, fasting plasma glucose were significantly different among the four groups in both genders. Blood pressure and HDL-cholesterol were significantly different among the four groups in women. The odds ratios of the 4th group (more than 75 percentile) of hs-CRP comparing with the 1st group (less than 25 percentile) for higher predicted risk were 3.6 in men and 4.2 in women. The associations were still significant but slightly weakened after further adjustment for central obesity. Hs-CRP, which is a marker of inflammation, was positively and significantly associated with FCRS and its components in overweight middle aged hospital employees.

1. Albert CM,Ma J,Rifai N(2002).Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death.Circulation,105,2595-2599.
2. Anderson KM,Odell PM,Wilson PWF(1991).Cardiovascular disease risk profiles.Am Heart J,121,293-298.
3. D`Agostino RB,Grundy S,Sullivan LM(2001).for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.JAMA,286,180-187.
4. Danesh J,Whincup P,Walker M(2000).Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.BMJ,321,199-204.
5. Devaraj S,Xu DY,Jialal I(2003).C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.Circulation,107,398-404.
6. Gill TP(2001).Cardiovascular risk in the Asia-Pacific region from a nutrition and metabolic point of view: abdominal obesity.Asia Pac J Clin Nutr,10,85-89.
7. Jousilahti P,Salomaa V,Rasi V(2001).The association of C-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease- baseline finding of the PAIS project.Atherosclerosis,1156,451-456.
8. Kennon S,Price CP,Mills PG(2001).The effect of aspirin on C-reactive protein as a marker of risk in unstable angina.J Am Coll Cardiol,37,1266-1270.
9. Koenig W,Löwel H,Baumert J(2004).C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany.Circulation,109,1349-1353.
10. Koenig W,Sund M,Froelich M(1999).Creactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men: results from MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992..Circulation,99,237-242.
11. Lagrand WK,Visser CA,Hermens WT(1999).C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?.Circulation,100,96-102.
12. Ledue TB,Rifai N(2003).Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment.Clin Chemistry,49,1258-1271.
13. Morrow DA,Rifai N,Antman EM(1998).C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.J Am Coll Cardiol,31,1460-1465.
14. Pasceri V,Cheng JS,Willerson JT,Yeh ET,Chang J(2001).Modulation of C-reactive proteinmediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.Circulation,103,2531-2534.
15. Pasceri V,Willerson JT,Yeh ET(2000).Direct proinflammatory effect of C-reactive protein on human endothelial cells.Circulation,102,2165-2168.
16. Pearson TA(2002).New tools for coronary risk assessment: what are their advantages and limitations?.Circulation,105,886-892.
17. Pearson TA,Mensah GA,Alexander WR(2003).Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the Am Heart Association.Circulation,107,499-511.
18. Reynolds GD,Vance RP(1987).C-reactive protein immunohistochemical localization in normaland atherosclerotic human aortas.Arch Pathol Lab Med,111,265-269.
19. Ridker PM(2003).Clinical application of C-reactive protein for cardiovascular disease detection and prevention.Circulation,107,363-369.
20. Ridker PM(2001).High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.Circulation,103,357-362.
21. Ridker PM,Buring JE,Cook NR,Rifai N(2003).C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.Circulation,107,391-397.
22. Ridker PM,Cushman M,Stampfer MJ(1997).Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.N Engl J Med.,336,973-979.
23. Ridker PM,Hennekens CH,Buring JE(2000).C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.N Engl J Med,342,836-843.
24. Ridker PM,Rifai N,Clearfield M(2001).for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.N Engl J Med,344,1959-1965.
25. Ridker PM,Rifai N,Pfeffer M(1999).Long-term effects of pravastatin on plasma concentration of C-reactive protein.Circulation,100,230-235.
26. Ridker PM,Rifai N,Rose L(2002).Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.N Engl J Med,347,1557-1565.
27. Ridker PM,Stampfer MJ,Rifai N(2001).Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.JAMA,285,2481-2485.
28. Rost NS,Wolf PA,Kase CS(2001).Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.Stroke,32,2575-2579.
29. van der Meer IM,de Maat MP,Kiliaan AJ(2003).The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study.Arch Intern Med,163,1323-1328.
30. Venugopal SK,Devaraj S,Yuhanna I(2002).Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells.Circulation,106,1439-1441.
31. Verma S,Li SH,Badiwala MV(2002).Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein.Circulation,105,1890-1896.
32. Wilson PWF,D`Agostino RB,Levy D(1998).Prediction of coronary heart disease using risk factor categories.Circulation,97,1837-1847.

1. 林麗娟、巫靜怡(2010)。健走運動對社區中老年人心血管危險因子之影響。大專體育學刊，12(4)，90-98。